ZimVie (NASDAQ:ZIMV - Get Free Report) is scheduled to be releasing its earnings data after the market closes on Wednesday, October 30th. ZimVie has set its FY 2024 guidance at 0.550-0.700 EPS.Persons that wish to listen to the company's earnings conference call can do so using this link.
ZimVie (NASDAQ:ZIMV - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by ($0.04). ZimVie had a negative net margin of 63.84% and a positive return on equity of 2.21%. The business had revenue of $116.81 million during the quarter. During the same quarter last year, the firm posted $0.17 earnings per share.
ZimVie Stock Down 1.2 %
Shares of ZIMV traded down $0.17 during trading on Wednesday, reaching $14.14. The company's stock had a trading volume of 90,324 shares, compared to its average volume of 324,107. The company has a fifty day moving average of $16.31 and a two-hundred day moving average of $16.96. ZimVie has a twelve month low of $6.52 and a twelve month high of $22.40. The company has a market cap of $385.87 million, a price-to-earnings ratio of -1.03 and a beta of 2.12. The company has a quick ratio of 1.43, a current ratio of 1.94 and a debt-to-equity ratio of 0.62.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC upped their price target on ZimVie from $20.00 to $23.00 and gave the company a "buy" rating in a research report on Friday, August 2nd.
View Our Latest Report on ZIMV
Insider Activity at ZimVie
In related news, major shareholder Camber Capital Management Lp sold 525,000 shares of the company's stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $17.71, for a total transaction of $9,297,750.00. Following the sale, the insider now directly owns 2,725,000 shares of the company's stock, valued at approximately $48,259,750. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.01% of the company's stock.
About ZimVie
(
Get Free Report)
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Featured Stories
Before you consider ZimVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ZimVie wasn't on the list.
While ZimVie currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
